Intellectual-property filing extends Cellantra’s address-plus-payload platform across LNP, lentiviral, AAV and other gene-delivery architectures
Cellantra, a preclinical in vivo gene-therapy biotechnology company developing precision-targeted delivery technologies, today announced the filing of a patent application covering A20T013, the company’s engineered monobody designed to bind the αvβ6 integrin and function as a modular cell-surface address ligand for gene-delivery systems.
A20T013 represents the “address” component of Cellantra’s address-plus-payload product architecture. Rather than limiting the ligand to a single therapeutic cargo or delivery vehicle, the company is developing A20T013 as a modular targeting element that may be incorporated into multiple gene-delivery configurations, including lipid nanoparticles (LNPs), lentiviral vectors, adeno-associated virus (AAV) vectors and other engineered nucleic-acid or gene-delivery systems.
The patent filing is intended to protect A20T013 itself, its αvβ6-binding applications, and its use as a targeting or address component in gene-delivery products across multiple vehicle classes and therapeutic payloads.
A Modular Address for Multiple Delivery Technologies
Cellantra’s platform is built around the premise that where a therapeutic is delivered and what it does once inside the cell are separable engineering problems.
Under this model, an address ligand such as A20T013 is selected to recognize an accessible extracellular cell-surface marker. That targeting element can then potentially be paired with different delivery vehicles and therapeutic cargos depending on the biological objective.
A20T013 is currently incorporated into the company’s A20T013/W2993 targeted mRNA-LNP program, where it is being developed together with the W2993 intracellular KRAS G12D payload and an inhaled delivery strategy.
Beyond that lead configuration, Cellantra believes the same address concept may provide a foundation for additional product architectures in which A20T013 is displayed, conjugated or otherwise incorporated into different gene-delivery vehicles.
Thomas, Chief Technology Officer of Cellantra, commented:
“We do not view A20T013 as simply an accessory to one LNP program. We view it as an address. If an engineered ligand can reproducibly recognize the intended cell-surface target, the strategic opportunity is to make that address portable across different delivery technologies and different genetic payloads.”
“Our objective is to separate targeting from the vehicle itself. An LNP may carry mRNA, a lentiviral vector may install a genetic program, and an AAV may deliver another form of gene expression—but each system faces the same fundamental question: can we direct the product toward the cells we actually want to reach? A20T013 is being developed to answer that question through αvβ6-directed targeting.”
“The patent filing is therefore broader than one product configuration. It reflects our strategy of building reusable targeting assets that can sit upstream of multiple gene-delivery modalities while allowing each final product to be independently engineered and validated.”
Expanding the Address-Plus-Payload Strategy
Cellantra’s development philosophy treats the therapeutic product as an integrated combination of four elements:
Address. A ligand designed to recognize a selected extracellular cell or tissue marker.
Vehicle. The delivery architecture carrying the therapeutic cargo, which may include LNP, lentiviral, AAV or other delivery systems.
Payload. The intracellular biological program, including mRNA-encoded proteins, gene-regulatory constructs, engineered receptors or other genetic cargo.
Route. The route of administration selected to support access to the intended tissue compartment.
By developing these components as interoperable but independently testable modules, Cellantra aims to create a portfolio in which validated targeting knowledge can be reused without assuming that performance automatically transfers between delivery vehicles.
Each A20T013-containing product configuration will therefore require its own confirmation of ligand presentation, binding, cellular uptake or transduction, biodistribution, payload expression, function and safety.
Building Intellectual Property Around the Address Layer
The A20T013 filing complements Cellantra’s intellectual-property strategy around intracellular payloads and integrated delivery products.
The company believes proprietary address ligands may become an important layer of value in next-generation gene delivery because they can potentially connect disease-relevant cell recognition with multiple therapeutic modalities.
Cellantra intends to continue developing A20T013 both within its existing targeted mRNA-LNP program and as a reusable targeting asset for future gene-delivery applications.
About Cellantra
Cellantra is a preclinical in vivo gene-therapy biotechnology company developing precision medicines based on an address-plus-payload product architecture.
The company’s approach combines engineered extracellular targeting ligands with intracellular therapeutic payloads and delivery technologies selected for the intended biological compartment. Its lead targeted mRNA-LNP programs include A20T013/W2993 and a second co-lead program using a distinct address with the shared W2993 KRAS G12D payload.
Cellantra is also developing additional gene-delivery and in vivo cell-engineering programs spanning engineered T-cell receptors, CAR-mRNA, additional KRAS-directed payloads and gene-editing applications.
The company’s strategy is to build reusable intellectual-property assets at the address, payload and delivery layers while requiring each integrated therapeutic product to establish its own evidence for delivery, function and safety.
Media / Corporate Contact
Cellantra
[Name]
[Email]
[Website]
All Cellantra programs are investigational and preclinical. References to potential use of A20T013 with LNP, lentiviral, AAV or other gene-delivery systems describe platform concepts and intellectual-property strategy and do not establish validated delivery, clinical safety or therapeutic efficacy for any such configuration. This press release contains forward-looking statements concerning research, development and intellectual-property activities. Actual results may differ materially.
